State Street Corp Theseus Pharmaceuticals, Inc. Transaction History

State Street Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.12 - $4.18 $5,291 - $10,433	2,496 Added 0.68%	371,156 $1.5 Million
Q3 2023 Nov 14, 2023	BUY	$2.66 - $10.04 $3,043 - $11,485	1,144 Added 0.31%	368,660 $991,000
Q2 2023 Aug 14, 2023	BUY	$7.28 - $11.82 $514,346 - $835,106	70,652 Added 23.8%	367,516 $3.43 Million
Q1 2023 May 15, 2023	BUY	$5.21 - $14.05 $132,245 - $356,631	25,383 Added 9.35%	296,864 $2.64 Million
Q4 2022 Feb 14, 2023	BUY	$4.69 - $8.36 $108,808 - $193,952	23,200 Added 9.34%	271,481 $1.35 Million
Q3 2022 Nov 15, 2022	BUY	$5.7 - $8.68 $82,011 - $124,887	14,388 Added 6.15%	248,281 $1.44 Million
Q2 2022 Aug 15, 2022	BUY	$5.04 - $14.05 $258,209 - $719,809	51,232 Added 28.05%	233,893 $1.29 Million
Q1 2022 May 16, 2022	BUY	$8.75 - $14.51 $488,818 - $810,601	55,865 Added 44.06%	182,661 $2.11 Million
Q4 2021 Feb 14, 2022	BUY	$8.98 - $20.09 $1.14 Million - $2.55 Million	126,796 New	126,796 $1.61 Million

1.03M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.